326903-68-8

Basic information

• Product Name: N-(3-nitrophenyl)-3-(trifluoromethyl)benzamide
• Synonyms: N-(3-nitrophenyl)-3-(trifluoromethyl)benzamide
• CAS NO: 326903-68-8
• Molecular Weight: 310.232
• Mol File: 326903-68-8.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: N-(3-nitrophenyl)-3-(trifluoromethyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-nitrophenyl)-3-(trifluoromethyl)benzamide(326903-68-8)
• EPA Substance Registry System: N-(3-nitrophenyl)-3-(trifluoromethyl)benzamide(326903-68-8)

Safety Data

• Hazardous Substances Data: 326903-68-8(Hazardous Substances Data)

Upstream product

• 2251-65-2 3-(Trifluoromethyl)benzoyl chloride 
• 99-09-2 3-nitro-aniline 
• 454-92-2 3-(trifluoromethyl)benzoic acid 

Downstream Products

• 926663-69-6 N-(3-aminophenyl)-3-(trifluoromethyl)benzamide 
• 1622869-10-6 C₂₁H₁₅F₃N₂O₂ 

Relevant articles and documents

Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment

Overexpression of EGFR is often associated with advanced stage disease and poor prognosis. In certain cancers, Src works synergistically with EGFR to promote proliferation, survival, invasion and metastasis. Development of dual-target drugs against EGFR and Src is of therapeutic advantage against these cancers. Based on molecular docking and our previous studies, we rationally designed a new series of azaacridine derivatives as potent EGFR and Src dual inhibitors. Most of the synthesized azaacridines displayed good antiproliferative activity against K562 and A549?cells. The representative compound 13b showed nM IC50 values against K562 and A549?cells, and inhibited EGFR at inhibition rate of 33.53% at 10?μM and Src at inhibition rate of 72.12% at 1?μM. Furthermore, compound 13b could inhibit the expression of EGFR, p-EGFR, Src and p-Src. Moreover, 13b efficiently inhibited the invasion of tumor cells and induced cancer cells apoptosis. Our study suggested that azaacridine scaffold can be developed as novel multi-target kinase inhibitors for cancer therapy.

Aza-acridine compound and preparation method and application thereof

The invention discloses a method for efficiently preparing an aza-acridine compound. The structural formula of the aza-acridine compound is shown as a formula I; the preparation method comprises the following steps: adding a 2-aminoquinoline-3-methanamide compound and a solvent under an air condition, and heating to reaction temperature; after the reaction is ended, separating and purifying to obtain multisubstituted acridine derivatives shown as the following formula, wherein the reaction temperature is 100 to 200DEG C, and the reaction time is 1 to 24 hours. A synthetic method of the aza-acridine compound, disclosed by the invention, has the advantages of scientificity, reasonability, simple and easily-operated synthesis process and high synthetic yield; a product is easy to purify. The invention also relates to the aza-acridine compound which can be used for inhibiting EGFR (Epidermal Growth Factor Receptor) and SrC, a preparation method of the aza-acridine compound, activity of a drug containing the aza-acridine compound and the application of the drug. The compound is shown in a formula II and can be used for preparing an EGFR and SrC activity inhibitor and a disease treatment medicine activated and mediated by the EGFR and the SrC.

2-Amino-1-phenyl-pyrrolo[3,2-b]quinoxaline-3-carboxamide derivates

The invention relates to compound characterized by a general formula (1), wherein n of R1n is 0, 1, 2, 3 or 4, in particular n of R1n is 0 or 1, and each R1 independently from any other R1